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Abstract
Cell-based therapies for acute and chronic liver 
diseases are under continuous progress. Mesenchymal 
stem/stromal cells (MSCs) are multipotent cells able to 
migrate selectively to damaged tissue and contribute to 
its healing and regeneration. The MSC pro-regenerative 
effect occurs due to their immunomodulatory capacity 
and their ability to produce factors that promote cell 
protection and survival. Likewise, it has been observed 
that part of their paracrine effect is mediated by 
MSC-derived extracellular vesicles (EVs). EVs contain 
proteins, lipids and nucleic acids (DNA, mRNA, miRNA, 
lncRNA) from the cell of origin, allowing for intercellular 
communication. Recently, different studies have 
demonstrated that MSC-derived EVs could reproduce, 
at least in part, the biological effects obtained by MSC-
based therapies. Moreover, due to EVs’ stability for long 
periods of time and easy isolation methods they have 
become a therapeutic option to MSCs treatments. This 
review summarizes the latest results achieved in clinical 
trials using MSCs as cell therapy for liver regeneration, 
the role of EVs in liver physiopathology and the 
potential of MSC-derived EVs as intercellular mediators 
and therapeutic tools in liver diseases.
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Core tip: Cell-based therapies for acute and chronic 
liver diseases are very attractive strategies. In 
particular, mesenchymal stem/stromal cells (MSCs) 
are multipotent cells able to induce protective and 
pro-regenerative effects in different liver diseases. 
The mechanism through which MSCs support tissue 
regeneration is via  secretion of paracrine factors, and 
solid evidence supports that part of these effects is 
mediated by extracellular vesicles (EVs). Therefore, EVs 
have become an attractive option in the research for 
new treatments in liver diseases.
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INTRODUCTION
A diverse set of toxic, metabolic, and inflammatory 
insults result in liver diseases and imply different 
degrees of inflammation, apoptosis, and necrosis of 
parenchymal cells[1-4]. For example, acute liver failure 
(ALF) is characterized by a massive and sudden death 
of hepatocytes that lead to abrupt hepatocellular 
and systemic dysfunction[3]. Similarly, in patients 
with chronic liver disease an important loss of viable 
parenchymal cells is observed[1,2,4]. Cirrhosis is caused 
by diverse chronic liver diseases, such as viral hepatitis 
and chronic alcoholism[1,2]. Moreover, increases in the 
prevalence of hypertriglyceridemia, obesity and diabetes 
in developed countries have resulted in an increase 
in the incidence of non-alcoholic fatty liver disease 
(NAFLD)[4,5]. This condition is characterized by a lipid 
accumulation in the liver that could lead to hepatocytes 
apoptosis and inflammation. Regardless the liver chronic 
disease origin, the apoptosis of hepatocytes results in 
extracellular matrix accumulation that will affect the 
liver histoarchitecture of liver and ultimately impair its 
function[4]. It is well known that mesenchymal stem/
stromal cells (MSCs) migrate toward injured organs 
where they can provide tissue protection and promote 
liver regeneration[6-8]. These properties make MSCs 
interesting tools to carry therapeutic genes in modern 
cellular-based therapeutic strategies[6]. It is accepted 
that the main mechanism through which MSCs support 
tissue regeneration is via secretion of paracrine 
factors[7,9]. However, solid evidence supports that part 
of these effects are mediated by extracellular vesicles 
(EVs)[10]. In this review, we first provide an update on 
clinical trials using MSCs in different liver diseases; 
second, the mechanisms involved in the therapeutic 
effects of MSCs; third, general EVs characteristics and 
their role in liver diseases, and finally, the role of MSC-
derived EVs as therapeutic tools for liver regeneration.
CLINICAL TRIALS INVOLVING THE USE 
OF MSCS IN LIVER DISEASES
Clinical investigations using MSCs to treat a broad 
spectrum of degenerative diseases, including liver 
diseases, are increasing steadily in recent years[11,12]. 
The first clinical trial using MSCs was started in 2005 
and 52 trials are registered up to now (CinicalTrial.gov 
and reviewed by Tsuchiya 2017[13]). MSCs are obtained 
from bone marrow in most of the studies, but other 
sources such as umbilical cord, adipose tissue and 
menstrual blood has also been tested (Figure 1A). It 
should be noted that, allogeneic transplantation is more 
commonly used than autologous (Figure 1B). Between 
liver diseases, most of the trials are destined to the 
treatment of liver cirrhosis (Figure 1C) and only 2 of 
them are in phase II/III (CinicalTrial.gov). Unfortunately, 
only 22 of 52 registered clinical trials have published 
their results (Table 1). It is important to mention that 
MSCs were administered after culture in vitro between 
passages 3 to 6. Regarding the administration route, 
MSC transplant was performed by peripheral vein[14-28], 
hepatic artery[29-33], portal vein[15,27] or directly into the 
spleen[16,34,35]. One study performed on 12 patients 
showed similar therapeutic effects when MSCs were 
injected into the spleen or intravenously[17]. 
In general, MSC administration in patients with 
different liver pathologies proved to be feasible and 
safe (Table 1). Regarding their efficacy, studies 
demonstrated that MSCs exert positive effects on liver 
function by increase in serum levels of albumin and 
improving coagulation or decreasing bilirubin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) 
and γ-glutamyltransferase (γ-GT)[17-19,21-24,26,29,31,33-35]. In 
addition, the MELD (Model for End-stage Liver Disease) 
and Child-Pugh scores were improved after MSC 
treatment[14-19,23,28-32,34] (Table 1). Furthermore, in some 
studies it was demonstrated that the application of 
MSCs not only improved patient’s quality of life but also 
modulated the immune response of patients[22,26,31]. In 
this sense, a randomized clinical trial using autologous 
BM-derived MSCs in patients with hepatitis B virus-
related liver cirrhosis resulted in an improvement of liver 
function, an increase in Treg cells, and a decrease in Th17 
cells, serum levels of interleukin (IL)-17, tumor necrosis 
factor alpha (TNF-α) and IL-6; in addition, tumor growth 
factor beta (TGF-β) levels were increased in comparison 
with control group[31]. Similar results were reported in 
a phase I/II clinical trial in patients with primary biliary 
cirrhosis (PBC) transplanted with allogeneic MSCs that 
showed a reduction in the number of CD8+ T-cells and 
an increment of Treg cells and IL-10 serum levels[22].
Recently, Suk et al[32] reported a phase II clinical trial 
comparing the effects of one or two doses of autologous 
BM-derived MSC therapy with a control group in alco-
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holic patients. The authors observed that liver fibrosis 
quantification diminished after cell treatment, although 
no significant differences in fibrosis area were found 
between one and two doses. Importantly, no evidence of 
tumor formation was found during the follow-up in the 
MSC-treated groups[32].
On the other hand, MSCs were used to diminish 
hepatocellular damage in acute liver diseases. Recently, 
a phase II clinical trial in acute-on-chronic liver failure 
compared the standard medical treatment with one 
dose of allogeneic BM-derived MSC therapy[28]. In 
this study, MSC treatment demonstrated to be safe 
and able to improve bilirubin levels and MELD score. 
Interestingly, MSC transplant increased survival rate 
and decreased severe infection events[28].
Long-term immunosuppression is frequently asso-
ciated with impairment in patients´ quality of life 
and increased risk of infection or cancer. Therefore, 
considering their immunomodulatory capacity, MSCs can 
be used to induce tolerance after liver transplantation. In 
this regard, Detry et al[25] reported that MSC infusion 3 d 
after liver transplant was feasible, safe and well tolerated. 
No opportunistic infections or de novo cancer were 
detected in 12 mo follow-up. However, no difference 
was observed in peripheral blood CD4+ T cell proportion 
and immunosuppression could not be withdrawn in 
MSC-treated patients. In addition, the administration of 
umbilical cord-derived MSCs as therapy to prolong graft-
survival in patients with severe ischemic-type biliary 
lesions after liver transplantation was also evaluated[24]. 
Six doses of MSCs were infused intravenously every 
2-4 wk, and patients were followed-up for 2 years and 
compared with a prospective cohort of patients treated 
with standard therapy. Remarkably, MSCs were safe, 
improved hepatic function, prolonged graft-survival and 
did not induce cancer or increase microbial infection 
events[24]. In conclusion, these results demonstrated 
that MSC therapy is a safe procedure, especially in 
the field of solid organ transplant where intense and 
prolonged immunosuppression is required. Moreover, 
MSC administration could prevent the development of 
opportunistic infections or de novo tumor formation. All 
considered, the promising information generated in the 
clinic opens the possibility for further studies to determine 
the optimal protocol conditions of MSC application 
needed to induce tolerance after liver transplant.
Application of MSCs for treatment of either acute 
or chronic liver diseases has a promising future in the 
clinic. In acute liver diseases, MSCs could have a role 
decreasing liver damage progression or as a bridge for 
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Figure 1  Mesenchymal stem/stromal cells clinical trials in liver disease. A: MSCs clinical trials classified by cell source; B: MSCs clinical trials classified by 
transplant type; C: MSCs clinical trials classified by liver disease treated. Data from http//www.clinicaltrial.gov. n: Number of clinical trials; MSCs: Mesenchymal stem/
stromal cells; BM: Bone marrow; UC: Umbilical cord; AT: Adipose tissue.
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Table 1  Mesenchymal stem/stromal cells clinical trials for liver diseases






Cell administration condition Phase Results Follow 
up
Side effects
Dose P  value Route
Mohamadnejad 
et al[14] 2007
Cirrhosis BM/Auto n = 4 1, 0.6 × 107 2-4 IV I MELD ↓ 12 mo None
Kharaziha et al[15] 
2009
Cirrhosis BM/Auto n = 8; 4 HBV 
1 HCV 1 
Alcohol 2 
Control
3.5 × 107 3-4 PV/IV I/II MELD ↓ 24 wk None
El-Ansary et al[16] 
2010




Peng et al[29] 2011 Cirrhosis (HBV) BM/Auto n = 158; 53 
MSC 105 
Control
3.4-3.8 × 108 3 HA I/II ALB ↑, MELD ↓ 48 mo None
Amer et al[34] 2011 Cirrhosis 
(HCV)
BM/Auto n = 40; 20 MSC 
20 Control
2 × 107 NA IS/IH I/II ALB ↑, C.P ↓, MELD 
↓








BM/Auto n = 25; 9 MSC 
6 Hep. Diff. 10 
Control
1 × 106/kg MSC 
or 40% HLCs and 
60% MSCs




Zhang et al[18] 
2012
Cirrhosis (HBV) UC/Allo n = 45; 30 MSC 
15 Control
0.5 × 106/kg every 
4 wk, 3 times
3-4 IV I/II ALB ↑, MELD↓, 
ascites ↓
48 wk None




UC/Allo n = 43; 34 MSC 
9 Control
0.5 × 106/kg every 
4 wk, 3 times





Cirrhosis BM/Auto n = 25; 14 MSC 
11 Control
2 × 108 3-4 IV II No beneficial effect 12 mo None
Wang et al[21] 2013 UDCA-resistant 
PBC
UC/Allo n = 7 0.5 × 106/kg every 
4 wk, 3 times
4 IV I/II ALP↓, γ-GT ↓, 
quality of life↑ 
(fatigue↓, pruritus↓)
48 wk None
Amin et al[35] 2013 Cirrhosis BM/Auto n = 20 10 × 106 2 IS I/II ALT ↓,AST ↓,BIL ↓, 
PT ↓, ALB↑, PT↑
24 wk None
Jang et al[30] 2014 Cirrhosis BM/Auto n = 11 5 × 107 every 4 wk, 
2 times
4-5 HA II C.P ↓, TGF-β ↓, 
α-SMA ↓, collagen-1 
↓, fibrosis ↓,
20 wk None
Wang et al[18] 2014 UDCA-resistant 
PBC
BM/Allo n = 10 3-5 × 105/kg 3-5 IV I/II ALT ↓, AST ↓, γ-GT, 
BIL ↓, IgM ↓, Tregs 
↑, IL-10↑, CD8+T 
cells↓
12 mo None
Salama et al[23] 
2014
Cirrhosis BM/Auto n = 40; 20 MSC 
20 Control
1 × 106/kg 0 IV II ALT↓, AST↓,BIL↓, 
ALB↑, PT↑, C.P↓, 
ascites ↓
26 wk NA
Xu et al[31] 2014 Cirrhosis BM/Auto n = 56; 27 MSC 
29 Control
0.75 × 106/kg NA HA II/III ALB↑, MELD↓, ↑ 
Tregs/Th17 cell 
ratio, IL-17↓, TNF-α
↓, IL-6↓, TGF-β ↑
24 wk NA
Suk et al[32] 2016 Cirrhosis BM/Auto n = 55; 18 
MSC (× 1 d) 19 
MSC (× 2 d) 18 
Control
5 × 107 (1 mo post 
BM asp.) /5 × 107 
(1 and 2 m post 
BM asp.)
4-5 HA II C.P ↓, fibrosis ↓ 12 mo None




UC/Allo n = 82; 12 MSC 
70 Control
1 × 106/kg; week 1, 
2, 4, 8, 12 and 16
4 IV II/III BIL↓,ALP↓, γ-GT ↓, 
graft survival ↑
24 mo None
Detry et al[25] 2017 Liver 
transplantation
BM/Allo n = 20; 10 MSC 
10 Control
1.5-3 × 106/kg; day 
3 post-transplant
2-3 IV I/II No beneficial effect 6 mo None
Sakai et al[33] 2017 Cirrhosis AT/Auto n = 4 6.6 × 105/kg 0 HA I ALB ↑, PT↓ 1 mo None
Shi et al[26] 2017 Liver 
transplantation
UC/Allo n = 20; 14 MSC 
13 Control
1 × 106/kg; every 
4 wk, 3 times
3-4 IV I ALT↓, AST↓, BIL 
↓, improve liver 
allograft histology, 
acute rejection↓ (↑ 
peripheral Tregs, 
↑ Tregs/Th17 cell 
ratio).
12 wk None




BM/Allo n = 7 1 × 106/kg; day 0 
and day 2 post-
transplantation
2-3 PV/IV I NA 24 mo None
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liver transplant. In chronic liver diseases, MSCs could 
contribute to decrease liver damage, to ameliorate 
the degree of fibrosis, and even to avoid the need 
for transplant in some particular cases. On the other 
hand, in the post-transplant setting, MSC therapy could 
extend the graft survival and/or decrease the amount of 
immunosuppression. However, it is extremely important 
to understand that therapeutic potential of MSCs is an 
open question, and the information regarding source of 
MSCs, culture conditions, pre-condition protocols before 
cell transplantation, administration route, number of 
doses, and time of treatment are very heterogeneous 
and standardization is needed.
MECHANISM OF ACTION OF MSCS IN 
LIVER REGENERATION
As detailed above, is necessary to understand the mecha-
nisms that mediate MSCs therapeutic effects prior to 
continuing with its clinical application. The understanding 
of MSC biology has grown considerably. In the last 
decade, many mechanisms involved in their regenerative 
potential have been identified. These mechanisms 
involve, at least in part, migration toward injured tissues, 
immunomodulatory properties, differentiation and/or 
secretion of regenerative factors, which induce cell 
survival and proliferation[7,9,36,37]. It has been described 
that MSCs can be recruited to inflamed tissue by 
classic mechanism of blood stream migration: Rolling, 
adherence to endothelium and transmigration[8,36]. The 
injured liver produces signals that induce migration 
and homing of different cell types[38,39]. Both, chronic 
and acute liver injury induce apoptosis and necrosis 
of hepatocytes and/or cholangiocytes, infiltration of 
leucocytes, monocytes and activation of Kupffer cells 
(KCs), liver sinusoidal endothelial cells (LSECs) and 
hepatic stellate cells (HeSCs)[2,3,40]. In this context, 
MSCs could be attracted by several chemokines, 
cytokines and factors secreted by the damaged liver 
microenvironment, such as IL-1β, IL-6, IL-8, monocyte 
chemoattractant protein-1 (MCP-1), growth-regulated 
protein (GRO), TNF-α, TGF-β1, platelet-derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF), 
and stromal cell-derived factor 1 (SDF-1) among others. 
Receptors for these chemoattractants were found to 
be expressed in MSCs allowing them to migrate to the 
injured liver[11,36].
The differentiation potential of MSCs has been 
considered one of the advantages for their regenerative 
application[7,41-43]. By definition, MSCs give rise to cells of 
mesodermal lineages including osteoblasts, adipoblasts 
and chondroblasts[44]. Furthermore, there are many 
reports demonstrating that MSCs might differentiate to 
ectodermal (neurons), endodermal (hepatocytes) as 
well as other mesodermal lineages (cardiomyocytes), 
but this field remains very controversial[7,41]. In 
this context, a putative mechanism postulated for 
liver regeneration was the MSC differentiation into 
hepatocyte-like cells[45]. A number of differentiation 
in vitro protocols were explored in MSCs obtained 
from bone marrow, adipose tissue or umbilical cord 
demonstrating that MSC-derived cells acquired 
characteristic markers and functions of immature and 
mature hepatocytes (reviewed in Fiore et al[7]). In fact, 
a clinical trial compared the effect of autologous BM-
MSCs undifferentiated or differentiated into hepatocyte-
like cells in patients with cirrhosis. Despite the 
improvement of liver function, there was no significant 
difference between undifferentiated or differentiated 
MSC-based treatment[17]. However, difficulties to study 
and reproduce the in vitro differentiation and in vivo 
tracking after their administration, makes the MSC 
differentiation to hepatocytes a controversial field. This 
difficulty is due, at least in part, to unspecificity and/or 
unreliability of methods/trackers/reagents frequently 
used for the identification of cells or the phenotype they 
might acquire after their transplantation[46,47]. It should 
be noted that track able MSCs by GFP expression is 
detectable in the liver up to 7 d after transplant and 
then the signal rapidly decreases in animal models[48]. 
Moreover, some evidence indicated that in spite of 
the MSC homing to the liver, the rate of differentiation 
to hepatocyte-like cells is very low (less to 1%)[49,50]. 
Together, this information demonstrates that the main 
regenerative effect of MSCs cannot be explained by the 
differentiation to hepatocyte-like cells. 
Broad scientific consensus states that the rege-
nerative effect of MSCs is due to paracrine mechanisms. 
The versatility of MSCs makes them able to differen-
tially express factors depending on the surrounding 
microenvironment[51]. In the context of liver fibrosis, 
it was observed that MSCs produce high levels of 
anti-apoptotic growth factors such as SDF-1, VEGF, 
hepatocyte growth factor (HGF) and insulin-like growth 
factor (IGF)-I[9]. Also, the release of HGF, fibroblast 
growth factor (FGF), IL-6, fibrinogen and TGF-α can 
induce hepatocyte proliferation[51]. In addition, HGF 
Lin et al[28] 2017 Acute-on-
chronic 
Cirrhosis (HBV)
BM/Allo n = 110; 56 
MSC 54 
Control
1-10 × 105 cells/
kg; 1/wk, 4 wk
5-6 IV I/II MELD↓, SR↑, 
infections↓
24 wk None
P: Passage; BM: Bone Marrow; Allo: Allogeneic; Auto: Autologous; IV: Intravenous Infusion; MELD: Model for end-stage Liver Disease; HBV: Hepatitis B 
Virus; HCV: Hepatitis C Virus; IS: Intrasplenic; IH: Intrahepatic; NA: Not available; HA: Hepatic artery; CP: Child-Pugh score; HLC: Hepatocyte-like cells; 
UC: Umbilical cord; SR: Survival rate; Cr: Creatinine; BIL: Bilirubin; PBC: Primary biliary cirrhosis; UDCA: Ursodeoxycholic acid; Hep. Diff.: Hepatocyte 
differentiated; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; γ-GT: γ-glutamyltrans
peptidase; Asp: Aspiration.
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and epidermal growth factor (EGF) can induce hepatic 
progenitor cell proliferation and differentiation[52] and 
VEGF increases angiogenesis, an important event 
for liver regeneration[53]. Moreover, IL-10, HGF and 
IGF-I produced by MSCs can reduce fibrogenesis by 
inhibition of HeSCs activation and proliferation[7,9]. MSCs 
also secrete factors involved in extracellular matrix 
remodeling and chemokines that attract immune cells 
which could modulate their function[51]. In this way, 
in vivo administration of conditioned medium (CM) 
obtained from MSC cultures can be effective to reduce 
liver injury. It was reported that the administration of 
MSC-derived CM significantly improved short-term 
survival in a D-galactosamine-induced rat model of 
fulminant hepatic failure[54,55]. Furthermore, MSC-CM 
therapy had great inhibitory effects on hepatocellular 
death reducing hepatocyte apoptosis in a 90%. In 
addition, an increase in liver regeneration programs and 
number of proliferating hepatocytes was observed[55]. 
Subsequently, it was demonstrated that EVs, present in 
CM, are partly responsible of the therapeutic effects of 
MSCs[10,56].
EXTRACELLULAR VESICLES
Although, EVs were described as intracellular mediators 
many years ago, they have recently generated great 
interest as therapeutic and diagnostic tools. Initially, 
“extracellular vesicle” was used to refer to all kind of 
vesicles released by cells. Nevertheless, the increased 
knowledge of their biology allowed to distinguish 
between different types of vesicles[57]. Exosomes 
(50-100 nm in diameter) are homogenous and the 
largest family of EVs and are different from microvesicles 
(100-1000 nm) and apoptotic bodies (500-2000 nm) in 
size and biogenesis[58]. While exosomes are originated 
from multivesicular bodies (MVBs), microvesicles 
are originated directly from plasma membrane and 
released to extracellular space[58]. At present, vesicles 
can only be fractioned according to their sizes and no 
specific markers have been described. Due to a large 
heterogeneity in methods of isolation and terminology 
in the past published results, in this review we will refer 
to exosomes and microvesicles as “EVs”. In order to 
define a minimal criteria for EV characterization, the 
International Society for Extracellular Vesicles (ISEV) 
suggests a semi-quantitative analysis for typical protein 
marker, such as CD9, CD63, CD81, Alix or TSG101, size 
analysis and morphology examination[59]. In addition to 
these specific proteins, EVs contain a large number of 
proteins (growth factors, cytokines, vesicles proteins), 
DNAs, mRNAs, microRNAs (miRNAs), long non-coding 
RNAs (lncRNAs)[57,59]. An interesting characteristic of EVs 
is that they can be charged with specific components of 
the cell of origin, and this “cargo” could be modified by 
different stimuli and microenvironment conditions[58]. As 
mentioned above, it has been demonstrated that EVs 
are involved in the paracrine effects of MSCs, but as EVs 
are implicated in many intercellular communications, 
we will first describe their implication in liver diseases. 
EVS IN LIVER DISEASES
EVs have been implicated in a number of physiological and 
pathophysiological processes, such as immune response, 
angiogenesis, tissue regeneration, tumorigenesis/metastasis 
and neurodegenerative diseases[60-62]. In patients with 
primary biliary cirrhosis it was demonstrated that serum 
exosomes are taken up by peripheral monocytes and 
dendritic cells, resulting in the up regulation of co-
stimulatory molecules[63]. Interestingly, serum circulating 
EVs present different miRNA composition in cirrhotic 
patients when compared with healthy controls[63,64]. Recent 
findings demonstrated that EVs are implicated in viral 
hepatitis, drug-induced injury, alcohol injury, non-alcoholic 
steatohepatitis and biliary injury[65,66].
EVs derived from parenchymal cells
Exosomes transport a variety of macromolecules 
that could act as signals between donor and recipient 
cells. In vitro studies demonstrated that liver paren-
chymal cells produce EVs that are involved in many 
physiological and pathophysiological processes[65,66]. 
For instance, it was demonstrated that there is an 
increase in the number of circulating exosomes with 
proliferative effect on hepatocytes after ischemia/
reperfusion injury[67]. Nojima et al[67] reported that EVs 
derived from hepatocytes, but no other liver cells can 
induce hepatocyte proliferation in vitro. It should be 
noted that hepatocyte-derived EVs exert their effect 
in a dose-dependent manner. Furthermore, their 
administration in mice under ischemia/reperfusion liver 
injury or after 70% hepatectomy promotes hepatocyte 
proliferation and liver regeneration. Similarly, Herrera 
et al[68] showed that hepatic progenitor cell-derived 
EVs promote hepatocyte proliferation, suppress cell 
death, and accelerate liver regeneration in rats after 
hepatectomy. The author suggested that this effect is 
mediated by the delivery of RNA by EVs to target cells. 
It is worth mention, that current data demonstrated 
that hepatocyte-derived exosome properties are 
mediated by fusion with target hepatocytes transferring 
their cargos[67,69,70]. For example, hepatocyte-derived 
EVs transfer neutral ceramidase and sphingosine kinase 
2 (SK2) within hepatocytes resulting in the induction 
of sphingosine-1-phosphate (S1P), a demonstrated 
promoter of cell proliferation[67] (Figure 2). Further 
studies of the same group showed that CXCR1 is 
required for packaging of SK2 into exosomes and 
CXCR2 regulates neutral sphingomyelinase activity and 
there by neutral ceramidase production[71]. 
On the other hand, hepatocyte-derived EVs in a 
nonalcoholic steatohepatitis (NASH) model interact with 
macrophages inducing an inflammatory phenotype[72] 
(Figure 2). Activation of the death receptor 5 (DR-5) 
expressed on hepatocytes by free fatty acid induces 
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there lease of EVs that could stimulate IL-1β and IL-6 
expression on macrophages[72]. On the same line, EVs 
derived from palmitic acid (PA) stimulated hepatoma cells 
(Huh7 and HepG2) induce a profibrogenic phenotype on 
HeSCs[73]. Moreover, the activation of HeSCs seems to be 
related with the presence of miRNA-122 and miRNA-192 
in the EVs[73] (Figure 2). Similarly, an increase in the 
number of circulating exosomes in mice is observed after 
chronic alcohol consumption[74]. Furthermore, in vitro 
incubation of hepatocytes with ethanol not only increases 
the release of exosomes but also allows monocyte 
activation through miRNA-122 horizontal transfer[74,75]. 
Remarkably, circulating EVs obtained from patients with 
alcoholic hepatitis show higher levels of miRNA-30a, 
miRNA-192 and, in particular, miRNA-122 than those 
obtained from heathy donors[74] (Figure 2). 
EVs have also been implicated in horizontal transfer 
of information in chronic hepatitis C infection between 
hepatocytes and HeSCs. Devhare et al[76] demonstrated 
that EVs derived from HCV-infected hepatocytes transfer 
viral RNAs that increases the expression of profibrogenic 
markers on HeSCs. Interestingly, these EVs carry miR-
19a that activates the STAT3 signaling, enhancing the 
expression of TGF-β and IL-6. Importantly, miR-19a up-
regulation was observed in HCV-infected hepatocytes 
and in sera of chronic HCV patients with fibrosis[76,77] 
(Figure 2). Moreover, Seo et al[78] demonstrated that 
EVs are implicated in HeSCs activation via toll-like 
receptor 3 with the subsequent activation of γδ T cell 



























































Figure 2  Extracellular vesicles as paracrine mediator in liver disease and therapeutics potential of mesenchymal stem/stromal cells. After ischemia 
reperfusion injury (I/R) or hepatectomy, hepatocytes (1) HPCs (2) release EVs with the ability to induce hepatocyte proliferation. (3) HPC-derived EVs stimulate 
LSECs and macrophages production of proliferative cytokines such as IL25 and IL17B. (4) On the other hand, free fatty acids induce the production of hepatocyte-
derived EVs that result in the activation of quiescent HeSCs and pro-inflammatory macrophages (M1). (5) During chronic hepatitis C virus infection, EVs secreted 
by HCV-infected hepatocytes induce activation of HeSCs. (6) EVs secreted by hepatocytes after alcohol injury (containing CD40L and miRNAs) induce activation of 
monocytes and HeSCs. It seems to be a balance between EVs derived from active or quiescent HeSCs that promotes or inhibits fibrogenesis. Activated HeSC-derived 
EVs induce activation of quiescent HeSCs trough CCN2 (7) and quiescent HeSCs inhibit activated HeSCs transferring Twist1 or miRNA199a-5p (8). LSEC-derived 
EVs could also regulate HeSC activation (9). MSC-EVs induce hepatocyte proliferation, reduce oxidative stress and apoptosis, and modulate inflammatory response 
by carrying GPX1 or SK2 (10). Engineered MSC-EVs transferring miRNA-122, miRNA 181 5p and miRNA-223 have potential effects. The effects of MSC-EVs on 
HeSCs, hepatic macrophages, LSEC and infiltrated cells populations remain poorly explored. Green arrows: Inactivation of HeSCs; Red arrows: Activation of HeSCs; 
Blue arrow: Proliferative effect; Colors spots represent EVs from different cell origin; NCDase: Neutral ceramidase; SK2: Sphingosine kinase 2; S1P: Sphingosine-1-
phosphate; IL: Interleukin; SK1: Sphingosine kinase 1; CCN2: Connective tissue growth factor; Twist1: Basic helix-loop-helix transcription factor; GPX1: Glutathione 
peroxidase 1; HCV: Hepatitis C virus; EVs: Extracellular vesicles.
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liver parenchymal cells, the role of cholangiocyte-derived 
EVs has been less studied. However, the presence of 
circulating EVs with altered miRNA composition and 
immunostimulatory functions on patients with PBC could 
suggest a role of cholangiocyte-derived EVs on this 
disease[63,64].
EVs derived from non-parenchymal cells
Non-parenchymal cells, including LSECs, Kupffer cells, 
lymphocytes, and HeSCs play a critical role in many 
liver diseases and use EVs for communication with 
neighbor cells during liver damage[65,66]. For instance, 
connective tissue growth factor (CCN2), a pro-fibrogenic 
mediator, is packaged into EVs produced by activated 
HeSCs. Then, exosome CCN2 can be delivered to 
other quiescent or activated HeSCs to induce trans-
activation[79]. On the other hand, EVs derived from 
quiescent but not from activated HeSCs transport Twist 
1 that suppress CCN2 on target cells through miR-214 
induction[80]. Furthermore, Chen et al[81] showed that 
miR-199a-5p is loaded in quiescent HeSCs-derived 
EVs and also regulates CCN2 expression and activity 
on target cells (Figure 2). It seems to be a balance 
between EVs derived from active or quiescent HeSCs 
that promotes or inhibits liver damage. In addition, 
LSECs are known to maintain the HeSC quiescence 
through direct cell-to-cell contact and paracrine factors 
secretion[82]. Wang et al[83] demonstrated that LSEC-
derived EVs have the ability to transfer Sphingosine 
kinase 1 (SK1) to regulate HeSC activation. In contrast, 
Ichinohe et al[84] demonstrated that progenitor hepatic 
cell-derived EVs stimulate LSECs and Kupffer cells to 
produce IL17B and IL25 resulting in proliferation of small 
progenitor hepatic cells (SPHCs) and liver regeneration 
(Figure 2). These findings evidence the importance 
of EVs derived from LSECs in affecting the activation 
state of neighboring cells. However, the mechanisms by 
which exosomes reach and attach target cells are not 
well understood. It has been reported that endocytosis 
of LSEC-derived EVs is mediated by the interaction 
between exosomal fibronectin and its ligand on the 
surface of HeSCs[83]. Additionally, integrin αvβ3 or α5β1 
and heparan sulfate proteoglycan are ligand for EVs-
HeSCs interaction and allow information transfer from 
endothelial cells[85].
Other important non-parenchymal cells involved in 
fibrogenesis are Kupffer cells and infiltrating macrophages. 
These cells are key players not only in fibrogenesis but also 
in fibrosis resolution and regeneration[86,87]. In alcoholic 
liver injury, hepatocyte-derived EVs enriched in miR-122 
sensitize macrophages to LPS and induce their production 
of pro-inflammatory cytokines[75]. Moreover, CD40L 
presence on hepatocyte-derived EVs during alcoholic 
hepatitis promotes macrophage activation and the switch 
to a pro-inflammatory profile[88,89]. In contrast, in vitro 
exposure of monocytes to alcohol increased their release 
of EVs, which in turn induce an anti-inflammatory M2 
profile of naïve monocytes[90]. Interestingly, EVs derived 
from alcohol exposed monocytes contain high levels of 
miR-27a that is known to induce M2 polarization[90,91] 
(Figure 2).
In summary, it has been determined that EVs 
play a key role on the pathophysiological response 
to liver damage. EVs allow the interaction between 
parenchymal cells and non-parenchymal cells, mainly 
HeSCs, Kupffer cells and LSECs, mediating their anti/
pro-fibrogenic state. The role of EVs in cell-to-cell 
communication during liver damage and the transfer of 
molecules, proteins and miRNAs is gaining importance 
in the field. Furthermore, this mechanism can be 
exploited for new therapeutic approaches or used as 
biomarkers in non-invasive methods. In line with this, 
it has recently been reported that MSCs release high 
levels of EVs that can mediate part of their therapeutic 
effects. Thus, considering the key role of EVs in liver 
cell communication, MSC-derived EVs (MSC-EVs) could 
be studied as a new therapeutic approach for hepatic 
regeneration strategies.
MSC-EVS AND THEIR POTENTIAL FOR 
LIVER REGENERATION
As described above, the main mechanism by which 
MSCs support the repair and regeneration of injured 
tissues is by releasing paracrine factors[7]. Recently, 
this paracrine mechanism was described to be partially 
mediated by EVs released by MSCs[10,56]. In vitro 
assays demonstrated that MSC-EVs induce hepatocyte 
proliferation and dedifferentiation into progenitor 
oval cells[92,93]. Therapeutic effects of MSC-EVs were 
demonstrated in pre-clinical models of acute kidney 
injury[94], and then in pathologies of heart, brain, kidney, 
muscle and liver[95].
Li et al[96] demonstrated that MSC-EVs reduced 
the degree of hepatic injury, collagen deposition and 
inflammation in mice with fibrosis induced by carbon 
tetrachloride (CCl4). The antifibrotic effect observed by 
MSC-EVs is mediated by the inactivation of TGF-β1/
Smad signaling pathway. Moreover, a reversion of the 
epithelial-to-mesenchymal transition (EMT) both in vivo 
and in vitro was observed after the EV treatment[96] 
(Figure 2). Therefore, EVs derived from human MSCs 
were effective in mice demonstrating that they preserve 
at least part of the immunomodulatory properties of the 
cells of origin.
As for liver fibrosis, the therapeutic capacity of 
MSC-EVs was also assessed in acute models of liver 
injury. Cheng et al[97] studied the effect of EVs derived 
from menstrual blood MSCs in a galactosamine/LPS 
mice model. MSC-EVs were able to enhance animal 
survival and reversion of liver failure through hepatocyte 
apoptosis inhibition and systemic inflammation reduction. 
In addition, in vitro assays showed that EVs are taken 
up by AML12 cells (hepatocyte cell line) resulting in the 
inhibition of apoptosis induced by galactosamine/LPS[97]. 
Similar results were observed by Haga et al[98] using EVs 
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derived from bone marrow MSCs in an animal model of 
acute liver failure. A relevant finding was the preservation 
of the biological activity of cryopreserved-EVs m up to 3 
mo, indicating the stability of EVs[98].
It is known that induction of oxidative stress in the 
liver results in severe hepatic diseases by inducing cell 
apoptosis. A protective and proliferative effect of MSC-
EVs in a lethal mice model induced by a single dose of 
CCl4 has been reported[99]. In addition, MSC-EVs inhibited 
hepatocyte apoptosis induced by acetaminophen and 
H2O2 and increased cell viability in vitro[99]. In this line, Yan 
et al[100] demonstrated that EVs derived from umbilical 
cord MSCs induced an antioxidant effect on hepatocytes. 
Glutathione peroxidase 1 (GPX1) delivered on MSC-EVs 
reduces the reactive oxygen species (ROS) intracellular 
levels and inhibits the oxidative stress-induced apoptosis 
in vitro and in vivo. Remarkably, authors demonstrated 
that a low dose of EVs (16 mg/kg of body weight) 
resulted in similar effects either by tail vein administration 
or oral gavage. In addition, Nong et al[101] tested the 
effect of EVs generated from MSC-derived Induced 
pluripotent stem cells (iPSCs) (MSC-iPSC-EVs) in hepatic 
ischemia-reperfusion (I-R) injury models. In vivo 
administration of MSC-iPSC-EVs in I-R injury mice model 
resulted in a decrease of oxidative stress response and 
apoptosis, and an increase of hepatocyte proliferation 
(Figure 2).Consistently, an amelioration of hepatic 
damage and inflammatory response was observed after 
EV treatment. It should be noted that MSC-iPSC-EVs 
keep the characteristics of EVs usually obtained from 
tissue-derived MSCs (bone marrow, adipose tissue and 
umbilical cord)[101]. In addition, it has been reported 
that MSC-iPSC-EVs could directly fuse with hepatocytes 
increasing the activity of sphingosine kinase (SK1). 
Moreover, the increase in SK activity will in turn increase 
the sphingosine-1-phosphate (S1P) levels affecting 
hepatocyte proliferation[93] (Table 2).
Although there is a great therapeutic potential of MSC-
EVs in liver protection and regeneration, it is mandatory 
to understand the mechanisms involved in their biological 
effects. One key point of research is to know the bio 
distribution of EVs after systemic administration in vivo. 
In vitro assays showed that EVs are taken up via integrin 
mediated endocytosis by target liver cells[67,85,90,97]. In 
addition, MSC-EV biodistribution after intravenous (IV) 
administration shows EVs uptake as fast as 3 to 6 h after 
injection in liver, spleen and lung cells[97]. Furthermore, 
Haga et al[98] reported that liver, spleen and lung from 
mice with fulminant hepatitis exert a higher uptake of 
MSC-EVs in comparison with organs from healthy mice. 
However, since these experiments have been carried out 
using lipophilic tracers, confirmation of these results with 
Table 2  Mesenchymal stem/stromal cells-derived extracellular vesicles in experimental models of liver disease
Ref. EVs Isolation/characteristics Experimental model Protocol Biological effects
Haga et al[98] 2016 Ultracentrifugation Size: 
46-116 nm Alix+ CD9+, CD81+
C57Bl mice. ALF, i.p. 20 
mg/body D-GalNAc + 0,3 
mg/body TNF-α
2 × 108 to 2 × 1010 i.p./i.v. ↑ Survival, ↑ F4/80, ↑ inhibitor 
MMP-1 and IL-6, ↓ inflammation 
and apoptosis, ↓ ALT/AST, ↓ ALP, ↓ 
EGF, SCF, IFN-γ, IP-10, IL-1α, MIP-3, 
MCP-1/3
Yan et al[100] 2016 Ultracentrifugation Size: 
30-100 nm CD9+, CD61+, 
CD63+
BALB/c-nu/nu mice, i.p. 
CCL4-induced ALF, 0.15-0.35 
mL/kg
8, 16, and 32 mg/kg i.v./oral ↓ Oxidative stress and apoptosis 
Induces ERK1/2 phosphorylation and 
Bcl2 expression Inhibits IKKB/NFkB/
casp9/3 pathway
Tan et al[99] 2014 TFF, 100.kDa MWCO filter 
Size: 55-100 nm
C57BL/6 mice. CCL4-induced 
ALF, i.p. 0.05 mL CCL4/kg
0.4 μg (100 μL) i.s. ↑ Cell viability: TAMH, THLE-2, and 
Huh-7 ↑ Hepatocytes proliferation 
↓ ALT/AST ↓ Casp 3/7 ↑ 
antiapoptoticBcl-xL
Chen et al[97] 2017 Centrifugation and Exoquick-
TC Size: 30-100 nm CD63+ 
and tsg101+
C57BL/6 mice. ALF, i.p. 
D-GalNAc 800 mg/kg and 
LPS 50 μg/kg
1 μg/μL i.v. ↑ Liver function and survival ↓ 
Apoptosis ↓ TNF-α, IL-6 and IL-1 ↓ 
Casp-3 ↓ Necrosis and inflammation
Nong et al[101] 2016 Ultracentrifugation and 
ultrafiltration Size: 50-60 nm 
CD9+, CD63+ and CD81+
Rats I/R injury 600 μg suspended in 400 μL 
of PBS i.v.
↑ GSH, GSH-PX and SOD ↓ AST/ALT 
↓ TNF-α, IL-6 and HMGB1 ↓ Casp-3 
and Bax
Du et al[93] 2017 Centrifugation and filtered 
by 0, 45-μm PVDF filter 
ExoQuick Size: 100-200 nm 
Alix+, CD63+ and CD81+
C57 mice I/R injury 2.5 × 1012 particles in 500 μL 
of PBS i.v.
↑ Hepatocytes proliferation ↑ 
SK activity and S1P formation. 
Hepatoprotective and proliferative 
effect abolished by the inhibition of 
SK or S1P receptor 1
i.p.: Intraperitoneal injection; i.v.: Intravenous injection; i.s.: Intrasplenic; MMP: Metalloproteinases; CCL4: Corbon tetrachloride; D-GalNAc: N 
Acetylgalactosamine; IL: Interleukins; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; EGF: Epidermal 
growth factor; SCF: Stem cell factor; TNF: Tumor necrosis factor; IFN: Interferon; IP: Inducible protein; MIP: Macrophage inflammatory protein; MCP: 
Monocyte chemotactic protein; ERK: Extracellular signal-regulated kinase; Bcl: B-cell lymphoma; TFF: Tangential flow filtration; MWCO: Molecular 
weight cut-off; ALF: Acute liver failure; TAMH: Transgenic mouse hepatocyte; THLE: T-antigen immortalized human liver epithelial; Casp: Caspase; 
GSH: Glutathione; GSH-PX: Glutathione peroxidase; SOD: Superoxide dismutase; HMGB: High mobility group box; PBS: Phosphate-buffered saline; SK: 
Sphingosine kinase; S1P: Sphingosine 1-phosphate.
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specific markers is necessary. The MSC-EV survival in 
circulation after being administered and the recognition 
pathways used by the target cells need to be studied in 
depth. Moreover, this knowledge could help to define 
the better scheme of doses, the time of treatment and 
the route of administration depending of the type of liver 
damage. In addition, conformation details of proteins and 
nucleic acids loaded in the EVs is required.
ENGINEERING MSC-EVS FOR LIVER 
REGENERATION
Recently, an increased interest has been shown by 
the research community to improve the efficiency 
and potency of EVs loading specific cargos[102]. As 
described above, the EVs produced by MSCs have 
useful properties that would allow them to be used as 
therapies in different liver pathologies[62], and advances 
in nanomedicine would allow to improve the technology 
to generate more effective EVs[102,103]. Thereby, 
engineered EVs can be generated with strategies based 
on covalent surface chemistry, hydrophobic insertions 
or membrane permeabilization. Moreover, modification 
of the parental cells through metabolic labeling, genetic 
modification or by insertion of exogenous material could 
also produce modified EVs. These engineered EVs could 
carry specific DNAs, mRNAs or non-coding RNAs to the 
specific cell[102].
Lou et al[104] demonstrated that miRNA-122 
expression in MSCs by lentiviral infection increased 
their therapeutic effect in a fibrosis model in mice. 
MiR-122 positively regulates proliferation and trans 
differentiation of HeSCs having an important role in liver 
fibrogenesis[105]. Authors demonstrated that in vitro 
miRNA-122 is transferred to HeSCs through MSC-EVs 
resulting in the regulation of genes involved in collagen 
maturation and cell proliferation[104]. Another strategy 
uses EVs derived from MSCs with transient expression 
of miRNA-181-5p as a therapeutic option in a liver 
fibrosis model[106]. As for miRNA-122, miRNA-181-5p 
was delivered by MSC-EVs reducing the fibrosis and 
the inflammatory state of fibrotic mice[106]. Moreover, in 
vitro experiments show that after reaching the target 
cell, miRNA-181-5p binds to3´-UTR of STAT3 and Bcl-2, 
which in turn down regulates TGF-β1 expression and 
induces autophagy in HeSCs[106]. Finally, in a model of 
autoimmune hepatitis, a cytoprotective effect of MSC-EVs 
engineered to charge miRNA-223 was observed. The in 
vitro experiments demonstrated that miRNA-223 levels 
were increased in hepatocytes after their incubation with 
the engineered EVs[107]. Similar results were observed 
in vivo with an increase of this miRNA in the liver and 
a reduction of its target gene NLRP3, and therefore a 
decrease in hepatocyte apoptosis[107] (Figure 2).
In summary, more information is needed not only to 
develop more efficient therapies for liver diseases based 
on MSC-EVs but also to engineer them to increase their 
efficacy and potency.
CONCLUSION 
MSCs-based therapy has emerged as a potent and 
innovative treatment for acute and chronic liver 
diseases. The safety and feasibility observed in the early 
clinical trials using MSCs have increased the interest to 
translate the use of these cells to the clinic. Moreover, 
pro-regenerative results and an improvement in the 
life quality of patients were observed. In ALF, MSCs 
could have a role decreasing liver damage progression 
due their immunomodulatory properties. In chronic 
liver diseases, MSCs could contribute to decrease liver 
damage and to ameliorate the degree of fibrosis. Even 
more, in both case MSC treatment could not only delay 
the transplant but also to avoid it in some particular 
cases. In addition, in the post-transplant setting, MSC 
therapy could extend the graft survival and/or decrease 
the amount of immunosuppression required. Although 
the main mechanism by which MSCs support the 
repair and regeneration of injured livers is by releasing 
paracrine factors, strong evidences demonstrated that 
this paracrine mechanism is mediated by EVs released 
by MSCs. Therefore, due to EVs’ stability for long periods 
of time and easy isolation methods they have become a 
therapeutic option to MSCs treatments in liver diseases. 
At present, EVs are strongly explored for therapeutic or 
diagnostic application, and more information is needed 
to develop more efficient tools for liver diseases based 
on MSC-EVs. However, it is important to understand 
that therapeutic potential of MSCs or its EVs is still a 
matter of debate. In addition, standardization of source 
of MSCs, culture conditions, pre-condition protocols for 
cell transplantation, administration route, doses and time 
of treatment is required. Nevertheless, considering that 
development of new therapeutic approaches for liver 
diseases is urgent, MSCs emerge as potent innovation. 
Thus, take advantage of the therapeutic potential of 
MSCs as promising tool for liver regeneration could 
attend to an important worldwide human health problem.
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